October 19, 2023
Authored and Edited by Daniel F. Klodowski; Umber Aggarwal; Deena Kablaoui Lanier; Elliot C. Cook; Aaron L. Parker
In July, the PTAB cancelled 366 (76.89%) instituted claims across 31 IPR and PGR Final Written Decisions, including decisions issued following remand from the Federal Circuit. After review, 89 (18.70%) instituted claims survived, and patent owners conceded 21 (4.41%) instituted claims through motions to amend or disclaimer. For comparison, the cumulative average cancellation rate of instituted claims in IPR, CBM, and PGR Final Written Decisions is about 73%.
On a per-case basis, no instituted or substitute claims survived in 18 (58.06%) decisions, all instituted claims survived in 3 (9.68%) decisions, and a mixed outcome occurred in 10 (32.26%) decisions. A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision.
In August, the PTAB cancelled 473 (81.55%) instituted claims across 35 IPR and PGR Final Written Decisions. In those decisions, 107 (18.45%) instituted claims survived, and patent owners did not concede any instituted claims through motions to amend or disclaimer.
On a per-case basis, no instituted or substitute claims survived in 26 (74.29%) decisions, all instituted claims survived in 5 (14.29%) decisions, and a mixed outcome occurred in 4 (11.43%) decisions.
Through August 31, 2023, the PTAB has cumulatively granted 619 (16.01%) proposed substitute claims in motions to amend while denying 3,248 (83.99%) proposed substitute claims in IPRs.
The overall cumulative instituted claim survival rate in IPRs, CBMs, and PGRs through August 31, 2023, broken down by technology center, is as follows:
The cumulative number of Final Written Decisions through August 31, 2023, separated by technology center, is as follows:
Copyright © 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Webinar
Building a Strong ADC Patent Portfolio – From Prosecution and Litigation Perspectives
May 15, 2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.